SELLAS LIFE SCIENCES ANNOUNCES POSITIVE PIVOTAL PHASE 3 REGAL TRIAL DATA SHOWING IMMUNOTHERAPEUTIC CANCER VACCINE, GALINPEPIMUT-S (GPS), DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Reuters · 1d ago

Please log in to view news